REFERENCES
1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107-11.
2. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72:2138-48.
3. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the american diabetes association. Diabetes Care. 2025;48:1057-82.
4. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75:659-89.
6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.
7. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-69.
8. ElSayed NA, Aleppo G, Aroda VR, et al. 4. comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023;46:S49-67.
9. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165:1080-8.
10. Sterling RK, Lissen E, Clumeck N, et al. ; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
11. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486-501.
12. Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol. 2020;57:613-8.
13. Mózes FE, Lee JA, Selvaraj EA, et al. ; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71:1006-19.
14. Younossi ZM, Paik JM, Henry L, Pollock RF, Stepanova M, Nader F. Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK). Ann Hepatol. 2025;30:101789.
15. Vilar-Gomez E, Lou Z, Kong N, Vuppalanchi R, Imperiale TF, Chalasani N. Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States Health Care System. Clin Gastroenterol Hepatol. 2020;18:2305-14.e12.
16. Davyduke T, Tandon P, Al-Karaghouli M, Abraldes JG, Ma MM. Impact of implementing a “FIB-4 First” strategy on a pathway for patients with NAFLD referred from primary care. Hepatol Commun. 2019;3:1322-33.
17. Viganò M, Pugliese N, Cerini F, et al. Accuracy of FIB-4 to detect elevated liver stiffness measurements in patients with non-alcoholic fatty liver disease: a cross-sectional study in referral centers. Int J Mol Sci. 2022;23:12489.
18. Bhuvanesswar KC, Srivastava BK, Amutha A, et al. Prevalence of hepatic steatosis and fibrosis in Asian Indian individuals with type 2 diabetes. Diabetes Ther. 2025;16:1797-811.
19. Mantovani A, Lombardi R, Dalbeni A, et al. Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: a multicenter cross-sectional study. Diabetes Obes Metab. 2026;28:644-53.
20. Caviglia GP, Ferro A, D’Ambrosio R, et al. Effectiveness of a model of care based on fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicenter study. Am J Gastroenterol. 2026;121:375-82.
21. Shaheen AA, Baguley E, Swain MG, et al. Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways. JHEP Rep. 2026;8:101735.
22. Heyens LJM, van Malde DPA, Dogay Us G, et al. ; MASLD research group. Is FIB-4 the right tool for screening for liver fibrosis? Ann Hepatol 2025;31:102176.
23. Makker J, Tariq H, Kumar K, et al. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: a prospective cohort study. World J Gastroenterol. 2021;27:523-33.
24. Yeo YH, Ho HJ, Huang TW, et al. Dynamic FIB-4 score changes and HCC risk in patients with MASLD and elevated liver enzymes: a nationwide cohort study. Liver Cancer. 2026;Epub ahead of print.
25. Zhou XD, Li YT, Kim SU, et al. ; VCTE-Prognosis Study Group, Paired Liver Biopsy Group. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol. 2026;24:394-406.
26. Anstee QM, Berentzen TL, Nitze LM, et al. Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2024;36:100780.
27. Schreiner AD, Zhang J, Moran WP, et al. FIB-4 as a time-varying covariate and its association with severe liver disease in primary care: a time-dependent cox regression analysis. J Clin Gastroenterol. 2024;58:917-22.
28. Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023-9.
29. Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME; NASHNET. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis. Gastroenterology. 2020;159:1985-7.e4.
30. van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology. 2024;167:357-67.e9.
31. Kim J, Ito T, Arai T, et al. Modified FIB-4 index in type 2 diabetes mellitus with steatosis: a non-linear predictive model for advanced hepatic fibrosis. Diagnostics. 2024;14:2500.
32. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277-86.
